Physician profile
George E Canellakis
NPI 1245280874
$4,269.79
in general payments reported to CMS, 2019-2025
23 companies · $481 in 2025
The $481 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,399 · 2020: $172 · 2021: $412 · 2022: $416 · 2023: $633 · 2024: $758 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,847 · Travel and Lodging: $24.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,847.34 |
| Travel and Lodging | $24.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neotract INC. | $1,260.76 | 2019-2020 | |
| Teleflex LLC | $1,106.84 | 2021-2025 | Urolift, Barrigel |
| Abbvie INC. | $422.75 | 2022-2025 | Botox, Lupron Depot |
| Ferring Pharmaceuticals INC. | $225.20 | 2024-2025 | Adstiladrin |
| Astellas Pharma US INC | $218.65 | 2019-2024 | Myrbetriq, Xtandi |
| Janssen Biotech, INC. | $200.53 | 2022-2024 | Erleada |
| Coloplast Corp | $158.28 | 2019-2025 | |
| Angiodynamics, INC. | $107.26 | 2023 | Nanoknife |
| Antares Pharma, INC. | $92.03 | 2024-2025 | Xyosted |
| Endo USA, INC. | $56.89 | 2025 | Xiaflex |
| Merck Sharp & Dohme LLC | $56.34 | 2023-2024 | Keytruda, Lynparza |
| Urogen Pharma, INC. | $51.34 | 2025 | |
| Axonics, INC. | $45.95 | 2022-2023 | Axonics |
| Progenics Pharmaceuticals, INC. | $43.18 | 2022-2024 | |
| Endo Pharmaceuticals INC. | $36.65 | 2022-2023 | Xiaflex |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $32.92 | 2024 | |
| Immunitybio, INC. | $26.34 | 2025 | |
| Blue Earth Diagnostics | $23.92 | 2024 | |
| Metuchen Pharmaceuticals | $22.86 | 2019 | |
| Calyxo, INC. | $21.97 | 2025 | Cvac Aspiration System |
| Novartis Pharmaceuticals Corporation | $21.85 | 2024 | |
| Karl Storz Endoscopy-America | $21.41 | 2019 | |
| Boston Scientific Corporation | $15.87 | 2023 | Spaceoar Vue System - 10ml |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw George Canellakis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.